Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Cash Flows (Unaudited)

v3.10.0.1
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Dec. 31, 2017
Operating Activities:          
Net loss     $ (9,050) $ (6,843)  
Adjustments to reconcile net loss to net cash used in operating activities:          
Change in value of warrant liability [note 6 and note 7 [f]]   $ (111)   (111)  
Depreciation and amortization [note 4]     220 191  
Deferred income tax (recovery) [note 2 and note 4]   (2,928)   (3,051)  
Stock-based compensation [note 7 [c] and note 7 [d]] $ 210 152 588 152  
Bargain purchase gain [note 2]   (1,272)   (1,272)  
Loss on disposition [note 2]   8,610   8,610  
Contingent value rights liability recovery [note 2]       (200) $ (200)
Changes in operating assets and liabilities:          
Amounts receivable     (16) (164)  
Prepaid expenses and other assets     212 (1,597)  
Accounts payable     245 400  
Accrued liabilities other     317 (1,123)  
Accrued clinical liabilities     (210) 162  
Accrued compensation     613 (685)  
Lease obligation     (1) 47  
Net cash used in operating activities     (7,082) (5,484)  
Financing Activities:          
Proceeds from the sale of preferred stock, common stock and warrants, net of issuance costs     12,193    
Proceeds from exercise of warrants, net of issuance costs     1,274    
Proceeds from purchase agreement with Lincoln Park Capital, net of issuance costs     1,280 1,129  
Taxes paid related to net share settlement of equity awards       (22)  
Net cash provided by financing activities     14,747 1,107  
Investing Activities:          
Purchase of property and equipment     (36)    
Proceeds on disposal of assets     10    
Purchase of investments     (1,390)    
Cash received on reverse merger of OncoGenex [note 2]       12,376  
Net cash provided by investing activities     (1,416) 12,376  
Effect of exchange rate changes on cash       7  
Net increase (decrease) in cash, cash equivalents and restricted cash     6,249 8,006  
Cash, cash equivalents and restricted cash at beginning of the period     5,556 15 15
Cash, cash equivalents and restricted cash at end of the period $ 11,805 $ 8,021 $ 11,805 $ 8,021 $ 5,556